


Updated 2015 Oct 2

Richard G Tozer**NAME** Richard G Tozer**ADDRESS** 11 Inglewood Drive
Hamilton, Ontario
Canada, L8P 2T2**EDUCATIONAL BACKGROUND****Degrees and Diplomas**

1990	MD, Medicine, McMaster University
1987	PhD, Biochemistry, University of Western Ontario
1983	BSc, Biochemistry, University of Western Ontario

Qualifications, Licensures and Certifications

1995	Special Competence Medical Oncology, Royal College of Physicians and Surgeons of Canada (The)
1995	FRCPC (Medical Oncology), Royal College of Physicians and Surgeons of Canada
1994	FRCPC, Royal College of Physicians and Surgeons of Canada
1991	Registration, Medical Council of Canada
1990	Registration, The College of Physicians and Surgeons of Ontario

Research Training

1995 - 1997	Terry Fox Fellowship, Institute for Molecular Biology and Biotechnology, McMaster University, Hamilton Regional Cancer Centre
-------------	---

Other Specialized Training

1993 - 1995	Chief Resident, (Medical Oncology Residency), Medical Oncology, McMaster University, Hamilton Regional Cancer Centre
1991 - 1993	Chief Resident (Medical Residency), Internal Medicine, McMaster University

Richard G Tozer

1990 - 1991 Comprehensive Internship, Internal Medicine, McMaster University

CURRENT STATUS AT MCMASTER

2006 - present Associate Professor, Oncology, CAWAR, Health Sciences, McMaster University

PROFESSIONAL ORGANIZATIONS

The Royal College of Physicians and Surgeons of Canada, Fellow

Canadian Medical Association, Member

Ontario Medical Association, Member

Canadian Medical Protective Association, Member

Canadian Association of Medical Oncologists, Member

EMPLOYMENT HISTORY

University Appointments

2006 - present Associate Professor, Oncology, CAWAR, Faculty of Health Sciences, McMaster University

2002 - 2006 Associate Professor, Medicine, CAWAR, Faculty of Health Sciences, McMaster University

1997 - 2002 Assistant Professor, Medicine, Special, Faculty of Health Sciences, McMaster University

Academic

1984 Laboratory Demonstrator, University of Western Ontario

Administrative

1998 - 2006 Director of Residency Program in Medical Oncology, McMaster University

Clinical

1997 - present Medical Oncologist, Juravinski Cancer Centre, Dept. of Medical Oncology

1992 - 1997 Physician Supervisor, Chedoke McMaster Hospitals, Cardiac Exercise Rehabilitation Program

Training

1995 - 1997 Terry Fox Fellowship, Institute for Molecular Biology and Biotechnology, McMaster University, Hamilton Regional Cancer Ctr

1993 - 1995 Medical Oncology Residency (Chief Medical Oncology Resident), McMaster University, Hamilton Regional Cancer Centre

Richard G Tozer

- 1991 - 1993 Internal Medicine Residency (Chief Medical Resident 1993), McMaster University
- 1990 - 1991 Comprehensive Internal Medicine Internship, McMaster University

SCHOLARLY AND PROFESSIONAL ACTIVITIES

External Grant Reviews

- 2003 - present Wellspring at Sunnybrook Regional Cancer Centre, Wellspring - Toronto

Reviewer

- 2009 External Review of Residency Program in Medical Oncology, Dalhousie University

Reviewer to CPSO

- 2011 William Osler Health Centre, Brampton
- 2011 Windsor Regional Hospital, Windsor
- 2010 Kingston Regional Cancer Centre, Kingston

Reviewer To CPSO

- 2009 Grand River Cancer Centre, Grand River

Other Professional Activities

- 2005 A Pilot Study of Exercise For Body Weight and Composition Maintenance in Premenopausal Breast Cancer Survivors
- 2005 Co-Principal Investigator: The Effect of Doxycycline On Biochemical Markers of Bone Turnover in Breast Cancer Patients with Skeletal Metastases. (MA.26)
- 2005 Co-Principal Investigator: A Phase III Trial of Observation +/- Tamoxifen For Good Risk Duct Carcinoma In situ of the female breast
- 2005 Co-Principal Investigator: A Phase III Adjuvant Trial of Sequenced EC + Filgrastim + Epoetin Alfa Followed by Paclitaxel vs. Sequenced AC Followed by Paclitaxel vs. CEF as Therapy For Premenopausal Woman and Early Postmenopausal Women Who Have Had Potentially Curative Surgery for Node Positive or High Risk Node Negative Breast Cancer. (MA.21)
- 2005 Local Principal Investigator: A Phase I/II Study of GW572016 In Patients With Recurrent Malignant Glioma (NCIC CTG Protocol: IND. 170)
- 2005 Local Principal Investigator: A Phase III Randomized Double-Blind Study of Adjuvant ST1571 (Gleevec, Imatinib) Versus Placebo In Patients Following the Resection of Primary Gastrointestinal Stromal Tumour (GIST) (NCIC CTG SRC.1)

Richard G Tozer

-
- 2005 Local Principal Investigator: A Randomized Phase II Study of Two Different Schedules Of RAD001C In Patients with Recurrent/Metastatic Breast Cancer (NCIC CTG Protocol Number: IND.163)
- 2004 Local Principal Investigator: A Phase II Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Pre-Menopausal Women With Endocrine Responsive Breast Cancer (SOFT)
- 2004 Local Principal Investigator: A Phase III Trial Evaluating the Role of Exemestane Plus GnRH Analogue as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer (Tamoxifen and Exemestane Trial (TEXT)
- 2004 Local Principal Investigator: A Phase III Study Of DPPE (Tesmiflifen) combined with Epirubicin and Cyclophosphamide Versus Epirubicin and Cyclophosphamide Alone As First-line Treatment in Metastatic /Recurrent Breast Cancer.
- 2004 Local Principal Investigator: An Open Label Study of AMG 706 in Subjects With Advanced Gastrointestinal Stromal Tumours (GISTs) Who Developed Progressive Disease or Relapsed While on Imatinib Mesylate (Amgen Protocol Number AMG 706 20040110
- 2004 Local Principal Investigator: A Phase II Study of SB-715992 (NSC 727990) in Previously Untreated Patients With Metastatic or Recurrent Malignant Melanoma (NCIC CTG Protocol Number: IND.169
- 2003 Local Principal Investigator: IMN 1207 Versus Casein In the Prevention of Wasting over Six Months During, or Following, Chemotherapy, Radiation, Or Surgery In the Treatment of Colorectal or Non-Small Cell Lung Cancer: A Multicentre, Randomized, Double-Blind Study
- 2003 Local Principal Investigator: A Randomized Phase III Trial of Exemestane Versus Anastrozole with or without Celecoxib in Postmenopausal Women with Receptor Positive Primary Breast Cancer (NCIC CTG Protocol Number MA.27.
- 2002 Local Principal Investigator: A Phase II Study of CC1-779 (NS 683864) in Metastatic Melanoma
- 2002 Local Principal Investigator: Chemotherapy for Radically Resected Loco-regional Relapse. A Randomized Clinical Trial of Adjuvant Chemotherapy For Radically Resected Loco-Regional Relapse of Breast Cancer. Chemotherapy Versus Observation
- 2001 Local Principal Investigator: Randomized Phase II-III Study in First Line Hormonal Treatment For Metastatic Breast Cancer With Exemestane or Tamoxifen in PostMenopausal Patients (NCIC CTG MA.23)
- 2001 Local Principal Investigator: A Pilot Open Label, Randomized, Comparative Study of Exemestane Versus Anastrozole in Post-Menopausal Breast Cancer Subjects with Visceral Disease
- 2000 Local Principal Investigator: ME.10-"Phase III Randomized Study of Four Weeks High Dose IFN- α 2b In Stage T3 – T4 or N1 (Microscopic) Melanoma"

Richard G Tozer

-
- 2000 Local Principal Investigator: SC.18-"A Phase III Double-Blind, Placebo-Controlled Randomized Comparison of Megestrol Acetate(Megace) Versus An N-3 Fatty Acid (EPA) Enriched Nutritional Supplement Versus Both for the Treatment of Cancer Cachexia and Anorexia"
- 2000 Local Principal Investigator: IND 137-"A Phase II Study of Flavopiridol in Patients with Previously Untreated Metastatic Malignant Melanoma"
- 2000 Co-Principal Investigator: "A Phase II Study Investigating Autologous CD34+ Derived Dendritic Cells Transduced with an Adenovirus Expressing Human gp 100 in Patients with Metastatic Melanoma"
- 1999 Co-Investigator: A Randomized controlled Trial to Assess the Effectiveness of Soy Milk in the Reduction of Hot Flashes in Menopausal Disease-Free Breast Cancer Patients
- 1998 - 1999 Co-Principal Investigator - "A Phase I Study Investigating Autologous CD34+ Derived Dendritic Cells Transduced with an Adenovirus Expressing Human gp100 in Patients with Metastatic Melanoma"
- 1997 - 1999 National Principal Investigator: A Phase II Trial of Troxacitabine in Patients with Metastatic Melanoma
- 1997 - 1998 Local Principal Investigator - "A Phase II Study of Bryostatin 1 given as a 24 hour Continuous Infusion Weekly in Patients with Advanced Malignant Melanoma" (IND.104)
- 1997 Local Principle Investigator NCIC CTG Trial MA.14: Tamoxifen Versus Tamoxifen Plus Octreotide in Post-Menopausal Females with Breast Cancer
- 1997 Local Principal Investigator "Phase III Randomized Study of Four Weeks High dose IFNa2b in Stage II-A Melanoma (NCIC CTG ME.10)"
- 1997 Local Principle Investigator - "A Phase III Randomized Double Blind Study of Letrozole Versus Placebo in Women with Primary Breast Cancer Completing Five or More Years of Adjuvant Tamoxifen" (NCIC CTG MA.17)
- 1997 The Role of Ets Proteins in Invasion and Metastases
- 1995 - 1997 Phosphorylation and Regulation of PEA3, a Nuclear Transcription Factor. Institute for Molecular Biology and Biotechnology. McMaster University, Hamilton, Ontario. Supervisor - Dr. J. Hassell
- 1993 - 1994 A Proposal for a Phase I/II Trial of Mofarotene and Tamoxifen in Women with Stage IV Breast Cancer. McMaster University, Hamilton, Ontario. Supervisor - Dr. A. Arnold
- 1992 - 1993 Efficacy of Thrombolysis at the Henderson General Hospitals; A Quality Assurance Project. McMaster University, Hamilton, Ontario. Supervisor - Dr. D. Sackett
- 1983 - 1987 Applications of Monoclonal Antibodies to Structure Function Relationships in Escherichia Coli F1-ATPase. University of Western Ontario, London, Ontario, Supervisor - Dr. S. Dunn
- 1982 - 1983 Characterization of Inter-Membrane Proteins in Escherichia Coli. University of Western Ontario, London, Ontario. Supervisor - Dr. T. Lo
-

Richard G Tozer

AREAS OF INTEREST**I. MEDICAL ONCOLOGY****HONOURS AND AWARDS**

1997	Chedoke McMaster Hospital Foundation, Research Grant (1997 - 1999)
1995	National Cancer Institute of Canada, Terry Fox Fellowship (1995 - 1997)
1992	Chedoke-McMaster Hospitals, Outstanding Resident Award (1992 - 1993)
1983	Ontario Graduate Scholarship (1983 - 1987)
1983	Graduate Entrance Scholarship
1981	Dean's List (1981 - 1983)
1979	Alexander Charles Spenser Entrance Scholarship

COURSES TAUGHT**Undergraduate Teaching**Physician Assistant Education Program

2012 Jul - 2015 Jun Supervisor, Elective, Interviewing, Examination and Reasoning, half-day (6)

Undergraduate Medical

2006 Jul - 2015 Jun Supervisor, Elective, Visiting Student, week per student (22)

1999 Jul - 2015 Jun Supervisor, Block Elective, week (29)

2005 Jul - 2014 Jun Student Advisor, group of 6 (9)

2009 Jul - 2010 Jun Supervisor, Elective, Horizontal, 4 weeks (4)

1999 Jul - 2009 Jun Supervisor, Horizontal Elective, week per student (6)

2005 Jul - 2007 Jun Planner, MF4, year (2)

2005 Jul - 2007 Jun Speaker, Large Group Session, MF 4, occasion (2)

2004 Jul - 2005 Jun Curriculum Contributor, Workshop Attendee, year (1)

1999 Jul - 2005 Jun Student Advisor, student per year (14)

Richard G Tozer

1999 Jul - 2002 Jun Co-ordinator, Electives, year (2)

1999 Jul - 2002 Jun Supervisor, Enrichment Year, student per year (2)

1999 Jul - 2000 Jun Supervisor, Elective, Horizontal, 1, Family Medicine, student (1)

1999 Jul - 2000 Jun Tutor, 1, year (1)

Undergraduate Medical Clerkship

2014 Jul - 2015 Jun Supervisor, Medical Subspecialties, rotation (1)

Graduate Teaching

Rehabilitation Science Graduate Program

2014 Jul - 2015 Jun Member, Comprehensive Examination, exam (1)

Postgraduate Teaching

Family Medicine and its subspecialties

2014 Jul - 2015 Jun Supervisor, Outpatient, clinic (1)

2014 Jul - 2015 Jun Supervisor, Inpatient, day (1)

Internal Medicine and its subspecialties

1999 Jul - 2014 Jun Presenter, Academic Half-Day, occasion (8)

1999 Jul - 2012 Jun Interviewer, Admissions, hour (34)

2009 Jul - 2010 Jun Interviewer, Admissions, 6 occasions
Core Internal Medicine Interviews (6)

1999 Jul - 2006 Jun Director, Subspecialty Program, year (7)

2003 Jul - 2004 Jun Co-ordinator, Academic Half-Days, year (1)

2003 Jul - 2004 Jun Member, Residency Training/Education Committee, Committee, year (1)

1999 Jul - 2004 Jun Presenter, Rounds, occasion (3)

1999 Jul - 2004 Jun Reader, Admissions, candidate (52)

1999 Jul - 2004 Jun Supervisor, Clinical, Out-patient/Ambulatory Care, half-day (10)

1999 Jul - 2004 Jun Supervisor, Clinical, Inpatient, day (151)

2001 Jul - 2002 Jun Research Advisor, resident per year (1)

Richard G Tozer

- 2001 Jul - 2002 Jun Supervisor, Research, Other Setting, week (52)
- 1999 Jul - 2002 Jun Supervisor, Block Elective, half-day (12)
- 1999 Jul - 2000 Jun Advisor/Mentor, resident per year (1)
- 1999 Jul - 2000 Jun Examiner, Mock Orals, half-day (3)
- 1999 Jul - 2000 Jun Presenter, Clinical Teaching Unit, occasion (6)
- 1999 Jul - 2000 Jun Presenter, Journal Club, occasion (1)
- 1999 Jul - 2000 Jun Resource Person, Academic Half-Day, occasion (1)

Oncology and its subspecialties

- 2014 Jul - 2015 Jun Facilitator/Resource, Clinical Teaching Unit, session (1)
- 2014 Jul - 2015 Jun Presenter, Other, presentation (2)
- 2014 Jul - 2015 Jun Supervisor Block Elective, week (1)
- 2014 Jul - 2015 Jun Supervisor, Clinical, Inpatient, (4 weeks), month (4 weeks) (1)
- 2014 Jul - 2015 Jun Supervisor, Outpatient, clinic (108)
- 2010 Jul - 2014 Jun Presenter, Academic Half-Day, occasion (5)
- 2010 Jul - 2014 Jun Supervisor, Clinical, Out-patient/Ambulatory Care, half-day (439)
- 2010 Jul - 2014 Jun Supervisor, Clinical, Inpatient, day (37)
- 2012 Jul - 2014 Jun Supervisor, Block Elective, half-day (68)
- 2012 Jul - 2013 Jun Interviewer, Admissions, hour (8)
- 2012 Jul - 2013 Jun Presenter, Rounds, occasion (1)
- 2012 Jul - 2013 Jun Reader, Admissions, candidate (6)
- 2010 Jul - 2011 Jun Instructor, Resident Individual Teaching Sessions, session (17)
- 2009 Jul - 2010 Jun Instructor, Resident Individual Teaching Sessions, 10 sessions
 Sara Kuruvilla, July 22, 2009 - May 31, 2010
 Brandon Meyers, August 17, 2009 - February 8, 2010 (10)
- 2009 Jul - 2010 Jun Presenter, ODT Rounds, 3 occasions
 Methods of Molecular Analysis, Part 1, October 2, 2009
 Methods of Molecular Analysis, Part 2, November 27, 2009
 Molecular Basics, May 14, 2010 (3)
- 2009 Jul - 2010 Jun Presenter, Academic Half-Day, 1 occasion
 Sarcoma - Systemic Therapy, August 12, 2009 (1)

Richard G Tozer

2009 Jul - 2010 Jun Supervisor, Clinical, Out-patient/Ambulatory Care, 135 half-days

Miranda Schell
 Amirtha Srikanthan
 Brandon Meyers
 Aalok Kumar
 Rachel VanderMeer
 Tark Ezzat
 Asma Ali
 Blair Leonard
 Ravi Ramjeesingh
 Rania Lingas
 Sergey Pozdnyakov
 Sabrina Allegro
 Cindy Quinton-Gladstone
 Chris Sharpe
 Sadiya Kukaswadia
 Mohamed Panju
 Julie Arsenault
 Sara Rask (135)

2009 Jul - 2010 Jun Supervisor, Clinical, Inpatient, 5 days
 Meena Mathivanan, April 26 - 30, 2010 (5)

Other

Continuing Education

2001 Jul - 2012 Jun Speaker, occasion (3)

2008 Jul - 2009 Jun Speaker, 1 occasion (1)

Learning Resources

2005 Jul - 2006 Jun Developer, Multi-Media, Resource, resource (13)

2005 Jul - 2006 Jun Member, Ad Hoc, Committee, year (1)

SUPERVISORSHIPS

Supervisory Committees

Medical Sciences

2008 Jul - 2010 Jun Member, Supervisory Committee, PhD Student
 Kristina Szabo-Davenport (2)

2006 Jul - 2008 Jun Member, Supervisory Committee, PhD Student
 Kristina Davenport (2)

2001 Jul - 2002 Jun Member, Supervisory, Committee, PhD, student per year (1)

Richard G Tozer

Rehabilitation Science Graduate Program

2013 Jul - 2015 Jun Member, Supervisory, Committee, PhD, student (2)

RESEARCH FUNDING

Grants (Primary Investigator's name is the first name listed)

- | | |
|---------------------|--|
| 2010 Jan - 2014 Oct | Walker, Irwin, Couban Stephen, Foley Ronan, Panzarella Tony, Roy, Schultz Kirk, Tozer Richard, A randomized trial of Thymoglobulin to prevent chronic graft vs host disease in patients undergoing hematopoietic stem cell transplantation from unrelated donors, Grant, Genzyme (GENZYM), Research - New Project, \$800,000.00 |
| 2009 Oct - 2014 Sep | Walker, Irwin, Couban Stephen, Foley Ronan, Panzarella Tony, Roy, Schultz Kirk, Tozer Richard, A randomized trial of Thymoglobulin to prevent chronic graft vs host disease in patients undergoing hematopoietic stem cell transplantation from unrelated donors, Grant, Canadian Institutes of Health Research (CIHR), Research - Clinical Trials, \$1,245,055.00 |
| 2009 Apr - 2010 Mar | Carvalho, Adriana, Tozer Richard, Psycho-oncology: A Pilot to Integrate Psychiatric Service into the Cancer Centre, Grant, Hamilton Academic Health Sciences Organization (HAHSO), Research - New Project, \$97,832.00 |
| 2003 Apr - 2009 Jun | Dhesy-Thind, Sukhbinder, Foley Ronan, Gaudie Jack, Levine Mark, Tozer Richard, A Phase I Study Investigating Multiple Injections of Autologous CD34+ Derived Dendritic Cells Transduced With an Adenovirus Expressing Rat Her-2/Neu in Patients with Metastatic Breast Cancer, Grant, Ontario Cancer Research Network (OCRN), Research - Clinical Trials, \$180,485.00 |
| 2002 Oct - 2005 Sep | Tozer, Richard, Singh Gurmit, Modulation of Ets proteins to regulate the spread of cancer., Grant, Canadian Institutes of Health Research (CIHR), Research - New Project, \$239,552.00 |
| 2000 Apr - 2002 Mar | Foley, Ronan, Dent Peter, Gaudie Jack, Levine Mark, McCulloch Peter, Tozer Richard, Wan Yonghong, Phase II Study Investing Multiple Injections of Autologous CD34+ Derived Dendritic Cells, Grant, Medical Research Council of Canada (MRC), Research - New Project, \$164,200.00 |
| 1998 Dec - 2002 Mar | Rozakis-Adcock, Maria, Lee Jonathan, Tozer Richard, HRCC Oncology Research Group, Grant, Canada Foundation for Innovation (CFI), Equipment - CFI New Opportunities Fund, \$326,706.00 |
| 1998 Dec - 2002 Mar | Rozakis-Adcock, Maria, Lee Jonathan, Tozer Richard, HRCC Oncology Research Group, Grant, Ministry of Energy, Science and Technology (MBST), Equipment - CFI New Opportunities Fund, \$359,377.00 |

Richard G Tozer

LIFETIME PUBLICATIONS (Principal Author is the first name on each of the entries below)

Peer Reviewed Contributions to Books

1. Hirte, H, Major, P, Dion, A, Foley, R, Tozer RG. Humanized Antibodies for Cancer Therapy: Part 2 Review clinical trials with Rituximab and Trastuzumab. *Current Oncology*, Vol. 6(3), October 1999.
2. Major PP, Cook RJ, Tozer RG, Hirte H. Evaluation of Bisphosphonates for the Management of complications of bone metastases in patients with breast cancer: Principles of clinical trial design and evaluation of published studies. *Current Oncology* 1998, Volume 5.
3. Foley, Ronin, Yonghong Wan and Tozer RG. Genetically Modified Dendritic Cells in Cancer Therapy: Implications for Transfusion Medicine.
4. Arnold A and Tozer RG. Retinoids and Lung Cancer. Sherbet (e4d).
5. Singh S, Barret J, Sakata K, Tozer RG, Singh G., ETS proteins and MMPs: partners in invasion and metastasis., *Curr Drug Targets*. 2002 Oct;3(5):359-67. Review.

Peer Reviewed Journal Articles

1. Chu QS, Nielsen TO, Alcindor T, Gupta A, Endo M, Goytain A, XU H, Verma S, Tozer R, Knowling M, Bramwell VB, Powers J, Seymour LK, Eisenhauer EA. A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent/metastatic sarcomas-NCIC-CTG IND 200†. *Ann Oncol*. 2015 May;26(5): 973-81. doi: 10.1093/annonc/mdv033. Epub 2015 Jan 28.
2. Easly AC, Coakley N, Cheng R, Cividino M, Savage P, Tozer R, White RE. Safe handling of cytotoxics: guideline recommendations. *Curr Oncol*. 2015 Feb;22(1):e27-37. doi: 10.3747/co.21.2151.
3. Mak IW, Evaniew N, Popovic S, Tozer R, Ghert M. A Translational Study of the Neoplastic Cells of Giant Cell Tumor of Bone Following Neoadjuvant Denosumab. *J Bone Joint Surg Am*. 2014 Aug 6;96(15):e127.
4. Granek L, Mazzotta P, Tozer R, Krzyzanowska MK. Oncologists' protocol and coping strategies in dealing with patient loss. *Death Stud*. 2013 Nov-Dec;37(10):937-52.
5. Granek L, Krzyzanowska MK, Tozer R, Mazzotta P. Oncologists' strategies and barriers to effective communication about the end of life. *J Oncol Pract*. 2013 Jul;9(4):e129-35. doi: 10.1200/JOP.2012.000800.
6. Goss PE, Ingle JN, Pritchard KI, Ellis MJ, Sledge GW, Budd GT, Rabaglio M, Ansari RH, Johnson DB, Tozer R, D'Souza DP, Chalchal H, Spadafora S, Stearns V, Perez EA, Liedke PE, Lang I, Elliott C, Gelmon KA, Chapman JA, Shepherd LE. Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27 --a randomized controlled phase III trial. *J Clin Oncol*. 2013 Apr 10;31(11):1398-404. doi: 10.1200/JCO2012.44.
7. Granek L, Krzyzanowska MK, Tozer R, Mazzotta P. Difficult patient loss and physician culture for oncologists grieving patient loss. *J Palliat Med*. 2012 Nov;15(11):1254-60. doi: 10.1089/jpm.2012.0245. Epub 2012 Sep 27.
8. Granek L, Mazzotta P, Tozer R, Krzyzanowska MK. What do oncologists want? Suggestions from oncologists on how their institutions can support them in dealing with patient loss. *Support Care Cancer*. 2012 Oct;20(10):2627-32. doi: 10.1007/s00520-012-1528-2. Epub 2012 Jun 20.

Richard G Tozer

9. Petrella TM, Tozer R, Belanger K, Savage KJ, Wong R, Smylie M, Kamel-Reid S, Tron V, Chen BE, Hunder NN, Hagerman L, Walsh W, Eisenhauer EA. Interleukin-21 has activity in patients with metastatic melanoma: a phase II study. *J Clin Oncol*. 2012 Sep 20;30(27):3396-401. doi:10.1200/JCO.2011.40.0655. Epub 2012 Aug 28.
10. Granek L, Tozer R, Mazzotta P, Ramjaun A, Krzyzanowska M. Nature and impact of grief over patient loss on oncologists' personal and professional lives. *Arch Intern Med*. 2012 Jun 25;172(12):964-6. doi: 10.1001/archinternmed.2012.1426.
11. Tap WD, Demetri G, Barnette P, Desai J, Kavan P, Tozer R, Benedetto W, Friberg G, Deng H, McCaffery I, Leitch I, Badola S, Chang S, Zhu M, Tolcher A. Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors. *J Clin Oncol*. 2012 May 20;30(15):1849-56. doi: 10.1200/JCO.2011.37.2359. Epub 2012 Apr 10.
12. Francescutti V, Farrokhyar F, Tozer R, Heller B, Lovrics P, Jansz G, Kahnemoui K. Primary tumor and patient characteristics in breast cancer as predictors of adjuvant therapy regimen: a regression model. *Cancer Chemother Pharmacol*. 2011 Sep;68(3):661-8. doi: 10.1007/s00280-010-1532-5. Epub 2010 Dec 2.
13. Szabo KA, Webber CE, Gordon C, Adachi JD, Tozer R, Papaioannou A. Reproducibility of peripheral quantitative computed tomography measurements at the radius and tibia in healthy pre- and postmenopausal women. *Can Assoc Radiol J*. 2011 Aug;62(3): 183-9. doi: 10.1016/j.carj.2010.04.011. Epub 2010 Jun 23.
14. Szabo KA, Webber CE, Adachi JD, Tozer R, Gordon C, Papaioannou A. Cortical and trabecular bone at the radius and tibia in postmenopausal breast cancer patients: a Peripheral Quantitative Computed Tomography (pQCT) study. *Bone*. 2011 Feb;48(2):218-24. doi: 10.1016/j.bone.2010.09.025. Epub 2010 Sep 24.
15. Pervaiz N, Colterjohn N, Farrokhyar F, Tozer R, Figueredo A, Ghert M. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. *Cancer*. 2008 Aug 1;113(3):573-81. doi: 10.1002/cncr.23592.
16. Lee CW, Belanger K, Rao SC, Petrella TM, Tozer RG, Wood L, Savage KJ, Eisenhauer EA, Synold TW, Wainman N, Seymour L. A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial. *Invest New Drugs*. 2008 Jun;26(3):249-55. Epub 2007 Oct 26.
17. Tozer RG, Tai P, Falconer W, Ducruet T, Karabadjian A, Bounous G, Molson JH, Droge W. Cysteine-rich protein reverses weight loss in lung cancer patients receiving chemotherapy or radiotherapy. *Antioxid Redox Signal*. 2008 Feb;10(2): 395-402.
18. Leighl NB, Dent S, Clemons M, Vandenberg TA, Tozer R, Warr DG, Crump RM, Hedley D, Pond GR, Dancey JE, Moore MJ. A Phase 2 study of perifosine in advanced or metastatic breast cancer. *Breast Cancer Res Treat*. 2008 Mar; 108(1):87-92. Epub 2007 Apr 26.
19. Knowling M, Blackstein M, Tozer R, Bramwell V, Dancey J, Dore N, Matthews S, Eisenhauer E. A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial. *Invest New Drugs*. 2006 Sep;24(5):435-9.
20. Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, Shenkier TN, Tozer RG, Palmer MJ, Shepherd LE, Liu S, Tu D, Goss PE. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. *J Clin Oncol*. 2006 Aug 1;24(22):3629-35. Epub 2006 Jul 5.

Richard G Tozer

21. Burdette-Radoux S, Tozer RG, Lohmann RC, Quirt I, Ernst DS, Walsh W, Wainman N, Colevas AD, Eisenhauer EA. Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma. *Invest New Drugs* 2004 Aug;22(3): 315-22.
22. Burdette-Radoux S, Tozer RG, Lohmann RC, Quirt I, Ernst DS, Walsh. Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma. *Invest New Drugs*. 2004 Aug; 22(3):315—22.
23. Crooks DL, Whelan TJ, Reyno L, Willan A Tozer, R, Mings D, Miller J. The Initial Health Assessment: an intervention to identify the supportive care needs of cancer patients. *Support Care Cancer*. 2004 Jan;12(1):19-24. Epub 2003 Sep 20.
24. Whelan T, Sawka C, Levine M, Gafni A, Reyno L, Willan A, Julian J, Dent S, Abu-Zahra H, Chouinard E, Tozer R, Prichard K, Bodendorfer, I. Helping patients make informed choices: a randomized trial of a division aid adjuvant chemotherapy in lymph node-negative breast cancer. *J Natl Cancer Inst*. 2003 Apr 16;95(8):581-7.
25. Richard G Tozer, Duivenvoorde, WC, Popovic SV, Lhotak, S, Seidlitz, E, Hirte, HW, Singh, G. Doxycycline decreases tumor burden in a bone metastasis model of human breast cancer. *Cancer Res*. 2002 Mar 15;62(6):1588-91.
26. Tozer, RG, Burdette-Radoux, Susan, Reinhard, Lohmann; Quirt, Ian; Ernst, Donald S; Walsh, Wendy; Wainman, Nancy; Colevas, Dimitrios; Eisenhauer, Elizabeth. NCIC CTG Phase II study of flavopiridol in patients with previously untreated metastatic malignant melanoma (IND137). Event 2002 ASCO Annual Meeting.
27. Jane M Barrett, Mark A Puglia, Gurmit Singh, and Richard G Tozer. Expression of Ets-related transcription factors and matrix metalloproteinase genes in human breast cancer cells. *Breast Cancer Res Treat*. 2002 Apr;72(3):227-32.
28. Sarka Lhotak, Leelamma J Elavathil, Snezana Vukmirovic-Popovic, Wilhelmina CM Duivenvoorden, Richard G Tozer & Gurmit Singh. Immunolocalization of matrix metalloproteinases and their inhibitors in clinical specimens of bone metastasis from breast carcinoma. *Clinical & Experimental Metastasis* 18: 463-470,2001.
29. Laing MA, Coonrod S, Hinton BT, Downie JW, Tozer, RG, Rudnicki MA, Hassell JA. Male sexual dysfunction in mice bearing a targeted mutant alleles of the PEA3. *Mol Cel Biol*. 2000 Dec;20(24):9337-45.
30. O'Hagen RC, Tozer RG, Symons M, McCormick F, Hassell JA. The Activity of the Ets Transcription Factor PEA3 is Regulated By Two Distinct MAPK Cascades. *Oncogene* 13: 1323-1333, 1996.
31. Tozer RG, and Dunn SD. The ϵ Subunit and Inhibitory Monoclonal Antibodies Interact with the Carboxyl-Terminal Region of the β Subunit of Escherichia Coli F1-ATPase. *J. Biol. Chem.* 262:10706-10711, 1987.
32. SD, Zadorozny VD, Tozer RG, and Orr LE. The ϵ Subunit of Escherichia Coli F1-ATPase. Effects on Affinity for Aurovertin and Inhibition of Product Release in Unisite ATP Hydrolysis. *Biochemistry* 26:4488-4493, 1987.
33. SD and Tozer RG. Activation and Inhibition of the Escherichia Coli F1-ATPase by Monoclonal Antibodies Which Recognized the ϵ Subunit. *Arch. Biochem. Biophys.* 253:73-80, 1987.
34. Tozer RG and Dunn SD. Column Centrifugation Generates an Intersubunit Disulfide Bridge in Escherichia Coli F1-ATPase. *Eur. J. Biochem.* 161:513-518, 1986.

Richard G Tozer

35. Dunn SD, Tozer RG, Antczak DF and Heppel LA. Monoclonal Antibodies to Escherichia Coli F1-ATPase. J. Biol. Chem. 260:10418-10425, 1985.

Peer Reviewed Journal Abstracts

1. Tozer, RG, Foley, Stephen; McCulloch, Peter; Dent, Peter; Ross, Cathy; Scheid, Elizabeth; Wan, Yong; Roberts, Bruce; Gaudie, JKK. Injection of Dendritic Cells transduced with an adenoviral vector is associated with minimal toxicity and negligible neutralizing anti-Ad antibodies. ASCO 2002.
2. Tozer, RG, McCulloch, Peter; Dent, Peter; Levine, Mark; Ross, Cathy; Scheid, Cathy; Gaudie, Jack; Dowaleski, Brenda; Wan, Yuan. ASCO. 2002.
3. Tozer, RG, Burdette-Radoux S; Belanger K; Davis ML; Lohmanmn RC; Rusthovern J Wainman N; Seymour L. NCIC CTG Randomized Phase II Study of two schedules of Bryostatin 1 (NSC339555) in patients with advanced metastatic malignant melanoma (Poster 2052). ASCO 1999.
4. Tozer, RG and Dunn SD. Generation of Disulfide Bridges Between the α and δ Sub-units of the Escherichia Coli F1-ATPase. Proc. Can. Fed. Biol. Soc. 29:198 (abstr. PO-263), 1986.
5. Tozer, RG and Dunn SD. Epitopes Recognized by Monoclonal Antibodies to the Escherichia Coli F1-ATPase. Proc. Can. Fed. Biol. Soc. 28:223 (abstr. PO-430), 1985.
6. Tozer, RG and Gurmit Singh; Barrett, Jane M; Puglia, Mark A; Kenji Sakata. Modulation of Ets Transcription Factor Target Gene Expression in Breast Cancer Cells.
7. Tozer, RG and Singh, Gurmit; Sakata, Kenji; Barrett, Jane. Role of PEA3 in Prostate Cancer.
8. Tozer, RG, Cox M; Ashraf U; Hassell JA. (OCF Symposium) PEA3 is a Direct Nuclear Target of Both the Extracellular Signal-Regulated and Stress-Activated Protein Kinases.

PRESENTATIONS AT MEETINGS

Contributed Peer Reviewed Presentations

1. Wellspring Calgary Review Calgary, Alberta, Canada. May 10, 2010.
2. Finds from Med IQ analysis of Jcc Chemotherapy Unit and Oncology Pharmacy Juravinski Cancer Centre. Hamilton, Ontario, Canada. Feb 10, 2010.

Conferences and Professional Annual Meetings

1. Keystone Symposium: Breast and Prostate Cancer Basic Mechanisms Taos, Mexico. 1996.

Conferences and Professional Annual Meetings Attended

1. World Melanoma Conference Vancouver, British Columbia, Canada. 2005.
2. San Antonio Breast Conference San Antonio, Texas, United States. 2004.
3. San Antonio Breast Conference San Antonio, Texas, United States. 2000.
4. San Antonio Breast Conference San Antonio, Texas, United States. 1999.

Richard G Tozer

5. American Society of Clinical Oncology Atlanta, Georgia, United States. 1999.
6. NCIC-EORTC Conference on New Drug Development Amsterdam, Netherlands. 1996.
7. Molecular Biology Workshop Aspen, Colorado, United States. 1994.
8. Retinoids in Oncology Meeting London, England, United Kingdom. 1994.

Wellspring Quality Review

1. Quality Review Panel Presentation Wellspring Niagara. Welland, Ontario, Canada. Oct 2009.

ADMINISTRATIVE RESPONSIBILITIES

2007 Jul - present	Lead, Regional Systemic Treatment Program, LHIN
2005 - present	Chair, Disease Site Team Council, Juravinski Cancer Centre
2007 Nov - 2014	Head, Systemic Treatment Programme, Juravinski Cancer Centre
2001 - 2007	Chair, Skin Disease Site Team Leader, Juravinski Cancer Centre

Division/Department

2014 Aug - present	Member, Telephone Triage Working Group, Juravinski Cancer Centre
2014 - present	Chair, RESSCU Model Working Group, Juravinski Cancer Centre
2014 - present	Member, JHCC Cancer Program Executive Committee, Juravinski Cancer Centre
1999 - 2014	Head, Dept of Supportive Care, Juravinski Cancer Centre

External

2009 Oct	Member, Royal College of Physicians and Surgeons of Canada Specialty Committee, Royal College of Physicians and Surgeons of Canada
2004	Vice-Chair, Royal College of Physicians and Surgeons of Canada, Medical Oncology Examination Board

Hospital

2015 Sep - present	Member, PAD Working Group, Hamilton Health Sciences
2015 Jan - present	Member, Oncology Operations and Quality Committee, Juravinski Hospital and Cancer Centre
2014 Aug - present	Member, Ambulatory Steering Committee, Juravinski Hospital and Cancer Centre
2014 Feb - present	Member, JCC Clinic Utilization Committee, Juravinski Hospital and Cancer Centre
2014 - present	Member, Electronic Health Record Working Group, Juravinski Hospital and Cancer Centre

Richard G Tozer

2013 - present	Member, JHCC Patient Flow and Innovation Steering Committee, Juravinski Hospital and Cancer Centre
2011 Dec - present	Chief of Oncology, Hamilton Health Sciences Corporation
2010 Aug - 2011 Nov	Acting, Chief of Oncology, Hamilton Health Sciences Corporation
2003 - 2006	Chair, Supportive Care Network, Central West Ontario, Juravinski Cancer Centre

University

1998 - 2006	Director, Residency Program in Medical Oncology, McMaster University
1993 - 1995	Chief Medical Oncology Resident, Medical Oncology Residency Training Programme, McMaster University
1993	Chief Medical Resident, Residency Programme, McMaster University